Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antimigraine drugs: new frontiers.

Literature DB >> 19415426

Antimigraine drugs: new frontiers.

Abstract

There are many acute care and preventive medications for the treatment of migraine. However, patients may often find that their headaches are not under optimal control. There are several targets that have been looked at and studied for the production of new, more effective medications. There are also effective devices for therapy of migraine. A list of targets will be put forth and a small number of them will be described in greater detail in this paper.

Entities: Disease Species

Mesh：

Substances：

Year: 2009 PMID： 19415426 DOI： 10.1007/s10072-009-0069-z

Source DB: PubMed Journal: Neurol Sci ISSN： 1590-1874 Impact factor: 3.307

12 in total

Review 1. New and future migraine therapy.

Authors: Nabih M Ramadan; Thomas M Buchanan
Journal: Pharmacol Ther Date: 2006-06-23 Impact factor: 12.310

2. Pharmacokinetics and safety of ketorolac following single intranasal and intramuscular administration in healthy volunteers.

Authors: Sarah D McAleer; Oneeb Majid; Esther Venables; Torsten Polack; Muhammed S Sheikh
Journal: J Clin Pharmacol Date: 2007-01 Impact factor: 3.126

3. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.

Authors: David W Dodick; Alexander Mauskop; Arthur H Elkind; Ronald DeGryse; Mitchell F Brin; Stephen D Silberstein
Journal: Headache Date: 2005-04 Impact factor: 5.887

4. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine.

Authors: Dan Levy; Rami Burstein; Andrew M Strassman
Journal: Ann Neurol Date: 2005-11 Impact factor: 10.422

5. Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans.

Authors: T A Armer; S B Shrewsbury; S P Newman; G Pitcairn; N Ramadan
Journal: Curr Med Res Opin Date: 2007-12 Impact factor: 2.580

6. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.

Authors: T W Ho; L K Mannix; X Fan; C Assaid; C Furtek; C J Jones; C R Lines; A M Rapoport
Journal: Neurology Date: 2007-10-03 Impact factor: 9.910

7. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler.

Authors: Stephen B Shrewsbury; Robert O Cook; Glyn Taylor; Ceri Edwards; Nabih M Ramadan
Journal: Headache Date: 2007-12-28 Impact factor: 5.887

8. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors: Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal: N Engl J Med Date: 2004-03-11 Impact factor: 91.245

9. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.

Authors: Tony W Ho; Michel D Ferrari; David W Dodick; Vince Galet; James Kost; Xiaoyin Fan; Heather Leibensperger; Samar Froman; Christopher Assaid; Christopher Lines; Hille Koppen; Paul K Winner
Journal: Lancet Date: 2008-11-25 Impact factor: 79.321

10. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.

Authors: Andrew M Blumenfeld; Jack D Schim; Thomas J Chippendale
Journal: Headache Date: 2007-11-28 Impact factor: 5.887

1 in total

Review 1. New acute treatments for headache.

Authors: Alan M Rapoport
Journal: Neurol Sci Date: 2010-06 Impact factor: 3.307

1 in total